CNBC — 2026-06-19#

Lead Story#

The fragile U.S.-Iran peace deal and the reopening of the Strait of Hormuz drove markets this week, sending oil prices tumbling below $80 a barrel. However, fresh uncertainty emerged after planned follow-up negotiations in Switzerland were abruptly canceled due to unresolved logistical issues, underscoring the immense challenges of forging a lasting regional settlement.

Markets & Economics#

The S&P 500 and Nasdaq ended the holiday-shortened week in the green, brushing off a mid-week selloff sparked by hawkish signals from new Federal Reserve Chairman Kevin Warsh. The central bank held rates steady but raised its year-end PCE inflation forecast to 3.6%, prompting traders to recalibrate expectations for elevated borrowing costs. In currency markets, Japan’s yen plunged past 161 against the U.S. dollar, nearing a 40-year low and reviving intervention bets despite the Bank of Japan’s recent rate hike and $73 billion in currency interventions last month.

Business & Earnings#

Apple CEO Tim Cook warned that “unavoidable” product price increases are imminent due to an “unsustainable” and AI-driven memory chip shortage. In the IT sector, shares of major Indian tech firms, including Infosys and TCS, slumped up to 7% after Accenture cut its full-year revenue growth guidance to between 3% and 4%. Elsewhere, India’s Jio Platforms filed draft papers for a massive initial public offering of up to 270 million shares, while retail investors in SpaceX’s historic IPO were left breaking even after a sharp post-debut pullback erased early gains.

Investing & Commentary#

Jim Cramer reiterated his bullishness on Intel, officially crowning it his “No. 1 name” over Nvidia following President Trump’s announcement of a U.S. chip design partnership between Intel and Apple. Wall Street analysts at Roth Capital initiated Nano Nuclear Energy with a buy rating, forecasting 60% upside as the company positions its micro-modular reactors to power the massive $700 billion AI data center buildout. Additionally, UBS analysts are urging investors to look past the high dropout rates of Zealand Pharma’s survodutide and pivot focus to its promising amylin-based obesity drug, petrelintide.

Also Worth Watching#

• U.S. opens tariff probe targeting Germany’s drug pricing policies: The U.S. launched a Section 301 investigation into Germany over “persistent underpayment” for pharmaceutical innovations that burden U.S. commerce.
• Russia threatens escalation after Ukraine hits Moscow with largest-ever drone attack: Ukraine launched a massive barrage of nearly 200 drones at a key Moscow oil refinery, prompting Russian threats of frequent and “massive group strikes”.
• NetJets’ first fatal crash kills influential Texas VC founder: A private jet belonging to Berkshire Hathaway subsidiary NetJets crashed in Texas, marking the fractional ownership company’s first fatal accident since it was acquired in 1998.
• Trump tells Axios he no longer views Anthropic as a national security threat: President Trump reversed his stance on Anthropic, stating he no longer views the AI firm as a security threat after it quickly complied with a directive blocking foreign nationals from accessing its advanced models.